LTA1 is a safe, intranasal enterotoxin-based adjuvant that improves vaccine protection against influenza in young, old and B-cell-depleted (μMT) mice

E. Valli1, A. J. Harriett1, M. K. Nowakowska1, R. L. Baudier1, W. B. Provosty1, Z. McSween1, L. B. Lawson1, Y. Nakanishi2 & E. B. Norton1*

Enterotoxin-based adjuvants including cholera toxin and heat-labile toxin (LT) are powerful manipulators of mucosal immunity; however, past clinical trials identified unacceptable neurological toxicity when LT or mutant AB5 adjuvant proteins were added to intranasal vaccines. Here, we examined the isolated enzymatic A1 domain of LT (LTA1) for intranasal safety and efficacy in combination with influenza (flu) vaccination. LTA1-treated mice exhibited no neurotoxicity, as measured by olfactory system testing and H&E staining of nasal tissue in contrast with cholera toxin. In vaccination studies, intranasal LTA1 enhanced immune responses to inactivated virus antigen and subsequent protection against H1N1 flu challenge in mice (8-week or 24-months). In addition, lung H1N1 viral titers post-challenge correlated to serum antibody responses; however, enhanced protection was also observed in μMT mice lacking B-cells while activation and recruitment of CD4 T-cells into the lung was apparent. Thus, we report that LTA1 protein is a novel, safe and effective enterotoxin adjuvant that improves protection of an intranasal flu vaccination by a mechanism that does not appear to require B-cells.

Vaccination is the most cost-effective method to prevent infectious diseases, yet 2.5 million deaths occur from vaccine-preventable illnesses annually1. Contributing to this problem are poor responsiveness to vaccines at the extremes of life and deficient protection at mucosal surfaces, as highlighted by recent influenza, pertussis, and polio studies2–4. In addition, vaccines are still needed for major intractable infections like HIV and tuberculosis5. Intranasal (IN) vaccination is an attractive delivery route due to the ease of administration (including possibility of self-administration), lack of injection-related infections, low antigen doses, and induction of robust systemic and mucosal immunity6–10. Adjuvants, such as aluminum salts, are useful additives to promote immunity to injected antigens. However, safe and effective IN adjuvants are lacking.

Perhaps the best-studied mucosal adjuvants are the enterotoxin proteins including heat-labile toxin E. coli (LT), cholera toxin (CT), and their derivatives6,11–13. To circumvent oral toxicity, LT was investigated for clinical use by nasal delivery. During 2000–2001, an LT-adjuvanted IN influenza vaccine was commercially available in Switzerland (Nasalflu, Berna Biotech). While efficacious, it was pulled from the market after a few months for safety issues; a subsequent investigation revealed a 19-fold higher risk of Bell’s palsy or facial paralysis in vaccine recipients14. Similar findings were observed with a detoxified mutant protein (LT-S63K)14,15. More recently, another mutant adjuvant, dmLT (LT-R192G/L211A), has exhibited success in Phase 1 and 2 clinical trials by non-IN mucosal and parenteral delivery routes11. Thus, LT adjuvants are potent mucosal adjuvants, but there is no candidate being considered for IN use.

LT and CT have an AB5 structure with an enzymatic A-subunit that is non-covalently associated with a pentameric B-subunit. The B-subunit is responsible for receptor binding and cellular entry by binding to cell surface...
The A-subunit can be proteolytically cleaved, creating an A1 domain that binds to cytosolic ADP-ribosylation factors and ADP-ribosylates the heterotrimeric G protein subunit Gs. This leads to irreversible adenylate cyclase activation, cAMP accumulation, and protein kinase A (PKA) activation, inducing target protein phosphorylation. In intestinal epithelial cells, this signaling cascade results in dysregulation of cellular membrane ion channels and ultimately intestinal secretion. However, in immune cells stimulated during vaccination (e.g., LT or dmLT admixed with antigen), this leads to promotion of antigen-specific immune responses, including antibodies (IgG, IgA) and multipotent CD4 T-helper (Th)1/Th17/Th2 responses in both systemic and mucosal tissue compartments. These adjuvant properties have been linked to stimulation of antigen-presenting cells (APCs) and inflammasome signaling.

The mechanisms underlying development of Bell’s palsy by enterotoxin-associated adjuvants are thought to involve both GM1-binding by the B-subunit and inflammation associated with the A-subunit within olfactory neuroepithelium. Antigen trafficking into the olfactory neuroepithelium can be blocked with pre-incubation of CT or LT with recombinant GM1. In addition, alterations in histopathology of the neuroepithelium and reduced neuronal firing and olfactory system function is observed with CT but not enzymatically inactive CT or purified B-subunit.

Therefore, one strategy to create a safe IN LT adjuvant is to remove the B-subunit. To that end, we recently began investigating the A-subunit and the A1 domain of LT (LTA1) for use as adjuvants. Both LTA1 and A-subunit proteins have ADP-ribosyltransferase activity, but, unlike LT, no GM1 binding by ELISA or gastrointestinal toxicity by patent mouse assay. Moreover, both proteins improved IN vaccine responses to co-delivered tetanus toxoid or ovalbumin in mice in contrast to non-enzymatically active LT B-subunit. By comparing combinations of LT proteins and subunits, we also observed that quality of the immune response (e.g., IgG1/IgG2 balance, mucosal IgA, and Th17 induction) was dependent upon the presence of an A-subunit. Additionally, while anti-A antibodies can neutralize LT toxicity, LTA1 is not a good antigen (in comparison with LT and LT) and does not induce robust autoantibodies. These studies highlighted two properties that make LTA1 unique among LT- and CT-derived adjuvants: low antigenicity and lack of a B-subunit or ganglioside binding.

In the current investigation, we expanded upon these early studies and tested the hypothesis that LTA1 is a safe, effective adjuvant for IN vaccination to enhance protection from disease using a flu model.

Results
LTA1 does not cause neurological toxicity as observed with nasal administration of AB5 enterotoxins. Previous nasal vaccines with LT adjuvants were found to be unacceptable due to neurological toxicity that was not apparent in pre-clinical studies. A newer methodology to evaluate IN toxicity of enterotoxins is olfactory behavioral testing which identifies effects on cranial nerve. To verify our hypothesis that the lack of a B-subunit and GM1-binding precludes development of neurological toxicity after LT1 IN administration, we performed a habituation-dishabitation test for olfactory system function (Fig. 1A). In this test, mice are first habituated to filter paper placement in their cage (containing mineral oil) then evaluated for subsequent investigation of new filter papers containing novel odors. In pilot analyses, we determined that 5–10 μg of CT IN was optimal for detection of olfactory system decline 24 h later (as higher doses limited mouse movement due to respiratory distress and lower doses were comparable to naïve mice, see Supplementary Fig. 1). We then treated mice with CT or 30 μg LTA1 IN and 24 h later performed the olfactory habituation-dishabituation test. Unlike CT-treated mice, LTA1-treated and untreated mice investigated cheese or shrimp odors significantly more times than their habituation control (i.e., in comparison with their third trial with mineral oil; Supplementary Video 1 and Fig. 1B). Compilation of all times investigating specific odors (from three trials) also indicated non-significant difference from LTA1-treated mice and untreated, whereas significantly lower investigations were observed with CT-treated mice in cheese and shrimp trials (Fig. 1C, respectively P = 0.07 or P < 0.01).

Although major histological changes in nasal tissue were not previously been reported with LT, we further examined mice post-behavioral testing for histopathologic changes in three H&E- or toluidine blue-stained transverse sections through the nasal cavity according to established guidelines and depicted in Fig. 2A (top). CT-treated mice exhibited neutrophil infiltration (arrows) and mild, acute inflammation in subepithelial tissue of nasal passages immediately posterior to the incisors and at the level of the incisive papilla but not by the second molar tooth and also a significantly higher level of mast cells (Fig. 2A,B and Supplementary Fig. 2). No significant inflammatory changes were detected in nasal passages of LTA1-treated or untreated mice. Thus, LTA1 exhibits improved neurological safety compared with an AB5 enterotoxin after IN delivery.

Immune responses to IN influenza immunization are enhanced with LTA1 adjuvant and exhibit dose-dependent responses for antibody generation. To investigate whether LTA1 can boost immunity to an IN vaccine, we used the inactivated antigen from the injectable split-virus commercial flu vaccine Fluzone® (FZ). FZ formulations at 3.6 μg total hemagglutinin (HA) content were admixed with 1, 5 or 10 μg LTA1 and delivered by prime/boost IN immunization to mice (days 0, 21) with sample analyses performed two weeks after either immunization (day 14 or 35) (Fig. 3A). For all analyses, two doses yielded higher levels of antibodies and recall cytokine responses than one and the addition of LTA1 adjuvant increased detectable FZ-specific responses (Fig. 3 and Supplementary Fig. 3). Significant induction of serum IgG1 in the FZ group was observed compared to naive animals on day 35, but only FZ + LTA1 groups developed antigen-specific serum IgG2a or bronchoalveolar lavage fluid (BAL) IgA. In general, development of antibody responses was adjuvant dose-dependent and maximal levels were observed with the highest dose of adjuvant (dark green bars, FZ + LTA1 10 μg, Fig. 3B).

We also evaluated memory cytokines responses to recall antigen using ex vivo cultured splenocytes (Fig. 3C,D). Robust cytokine secretion was observed in the FZ group compared to the naive group including Th1 cytokines (INF-γ, IL-2, TNFα) and other cytokines or proteases linked to protection from flu (GM-CSF, IL-12, INF-γ, IL-2, TNFα).
MIP-1β). Inclusion of LTA1 augmented these responses and also promoted generation of secreted factors IL-6 and Granzyme B (a serine protease that contributes to apoptosis of infected cells)29,30. However, with a few exceptions (e.g., Granzyme B, GM-CSF), the level of cytokine secretion was not adjuvant dose-dependent. Thus, pursuant to these results, we chose the 10 μg LTA1 dose for subsequent animal studies.

**LTA1 adjuvant enhances protection from H1N1 flu challenge in FZ-vaccinated mice.** We next examined if mice immunized with FZ and LTA1 adjuvant would improve protection from H1N1 challenge. First, we immunized mice with IN delivery of FZ alone or with 10 μg LTA1 (FZ + LTA1), then challenged them 2 weeks later with lethal pandemic Influenza strain A/California H1N1 (Fig. 4A). All mice were monitored for mortality and morbidity (e.g. weight loss). We found this single FZ + LTA1 immunization resulted in 100% protection from H1N1 mortality compared with only ~60% survival after FZ immunization (P = 0.06, Fig. 4B). FZ + LTA1 animals initially exhibited weight loss on days 2–4 post-challenge but recovered more rapidly than did FZ-immunized animals (*P ≤ 0.05 for weight loss on study days 6–11 post-challenge, Fig. 4C). We also observed improved protection from H1N1 survival and weight loss in a prime/boost model with 24-month old mice immunized with FZ + LTA1 compared to FZ (Supplementary Fig. 4). In conclusion, LTA1 adjuvant improves vaccine-mediated protection from H1N1 challenge in mice.

**LTA1-mediated protection from H1N1 flu challenge is associated with lower lung viral titers, acute-phase response IL-6 cytokine, and higher serum IgM, IgG, and IgA antibodies.** We next examined if mice immunized with FZ and LTA1 adjuvant would improve protection from H1N1 challenge. First, we immunized mice with IN delivery of FZ alone or with 10 μg LTA1 (FZ + LTA1), then challenged them 2 weeks later with lethal pandemic Influenza strain A/California H1N1 (Fig. 4A). All mice were monitored for mortality and morbidity (e.g. weight loss). We found this single FZ + LTA1 immunization resulted in 100% protection from H1N1 mortality compared with only ~60% survival after FZ immunization (P = 0.06, Fig. 4B). FZ + LTA1 animals initially exhibited weight loss on days 2–4 post-challenge but recovered more rapidly than did FZ-immunized animals (*P ≤ 0.05 for weight loss on study days 6–11 post-challenge, Fig. 4C). We also observed improved protection from H1N1 survival and weight loss in a prime/boost model with 24-month old mice immunized with FZ + LTA1 compared to FZ (Supplementary Fig. 4). In conclusion, LTA1 adjuvant improves vaccine-mediated protection from H1N1 challenge in mice.

**LTA1-mediated protection from H1N1 flu challenge is associated with lower lung viral titers, acute-phase response IL-6 cytokine, and higher serum IgM, IgG, and IgA antibodies.**
wanted to confirm our survival and weight loss results by evaluating if viremia or acute-phase response cytokine IL-6 during H1N1 challenge would be similarly improved by the addition of LTA1 adjuvant to vaccination. To do so we tested level of H1N1 viral RNA or IL-6 RNA in the lungs of mice day 3 or day 6 post-challenge comparing unvaccinated, FZ-vaccinated, or FZ+LTA1 vaccinated groups after 1 or 2 immunizations (Fig. 4D–I). In all instances, we observed significantly lower levels of lung H1N1 viral RNA in the FZ+LTA1 mice compared the FZ only group (P < 0.05 for day 6 post-H1N1 in primed animals; P < 0.001 for day 3 or 6 post-H1N1 in prime/boosted animals; Fig. 4D,G). Similarly, we observed significantly lower levels of lung IL-6 RNA in the FZ+LTA1 mice compared the FZ only group (P < 0.05 for day 6 post-H1N1 in primed animals; P < 0.001 for day 3 or P < 0.05 day 6 post-H1N1 in prime/boosted animals; Fig. 4E,H). Using data collected from all animals, we also observed that the level of viral RNA significantly correlated to lung IL-6 for each experimental conditions (Spearman’s P < 0.001 and r > 0.7; Fig. 4F,I).

We also evaluated serum FZ-specific IgM, IgG, and IgA antibody responses and number of total CD19+B-cells in the lungs from these animals post-challenge (Fig. 5A,B). We observed significant changes in post-challenge levels of serum IgM, IgG, and lung B-cells post-challenge in mice immunized with FZ+LTA compared to those immunized just with FZ after 1 immunization or 2 immunizations (P < 0.05 or greater). Serum IgA responses were also elevated in the FZ+LTA1 group, but only significantly different from FZ at 6-days post-H1N1 challenge after prime immunization (P < 0.05). Using data collected from all animals all timepoints, we also observed that the level of serum IgM, IgG, or IgA significantly and inversely correlated to levels of lung H1N1 viral RNA (Spearman’s P < 0.001 and r < −0.65; Fig. 5C). Thus, LTA1 immunized animals were better protected from high levels of H1N1 viral replication as well as viral associated acute phase responses IL-6 cytokine secretion while exhibiting higher levels of humoral immune responses post-challenge (anti-FZ serum antibodies).

**LTA1-mediated protection from H1N1 flu challenge does not require B-cells.** B-cells are critical to protection from influenza, as mice lacking mature B-cells (μMT mice) have worse survival outcomes post-challenge31. In addition, changes in serological responses (e.g., HA-neutralizing antibody titers) are the primary correlate of vaccine efficacy for existing or new clinical influenza vaccines32. We also observed higher levels of B-cells and serum antibodies in FZ+LTA1 vaccinated animals than in other tested groups (Fig. 5). To investigate if the protective effects of LTA1 adjuvant flu vaccine require intact humoral responses, we immunized μMT mice with FZ+LTA1 twice on days 0, 21 and then compared their responses to lethal H1N1 infection on day 35 with that of naïve μMT mice. Immunized mice were completely protected from mortality after flu challenge (P < 0.001) and also exhibited minimal weight loss compared with naïve μMT mice (significant beginning day 6 post-infection; Fig. 6A).

To confirm these results, we next evaluated animals from μMT or C57BL/6 (wild-type or WT) mice 6 days after H1N1-challenge who had been immunized prime/boost with either FZ or FZ+LTA1. Similar to previous results
(Fig. 4), we observed lower lung H1N1 viral levels in FZ + LTA1 mice compared with FZ in either μMT or WT strains (P < 0.01 in μMT mice or P < 0.001 in WT mice, Fig. 6B). In addition, all μMT mice irrespective of immunization history had significantly reduced levels of % or total lung CD19 + B-cells (Fig. 6C–E) and no detectable anti-FZ serum IgM, IgG, or IgA 6-days post-H1N1 challenge (Fig. 6F). No differences in B-cells or antibody levels were observed between FZ or FZ + LTA1 groups in μMT mice. Thus, despite previously observed humoral effects with FZ + LTA1 immunization, the protective effects of LTA1-adjuvanted flu vaccine is not dependent upon B-cells.

LTA1-mediated protection from H1N1 flu challenge is associated with lung CD4 T-cells. Since B-cells were not required for LTA1 mediated protection from flu challenge, we next evaluated changes to other immune cell populations in the lungs of μMT or WT mice 6 days after H1N1-challenge who had been immunized prime/boost with either FZ or FZ + LTA1. We observed higher levels of % CD3 T-cells and lower % of levels of NK cells recruited into the lungs of FZ + LTA1 μMT or WT groups post-challenge (P < 0.05 or greater, Fig. 7A,B). Within this CD3 T-cell population in both mouse strains, the proportion of CD4 T-cells was greater in FZ + LTA1 animals (P < 0.001, Fig. 7C), while % of CD8 T-cells or NKT cells were smaller or not-significantly different. Further evaluation in WT mice, indicated that CD4 T-cells in the FZ + LTA1 animals were also expressing significantly high levels of early activation marker CD69 than unvaccinated or FZ mice on days 3 and 6 post-H1N1 challenge (P < 0.001, Fig. 7D,E). Evaluation of INFγ RNA levels in the lungs of these mice was not significantly different between vaccinated mice groups (Fig. 7F), indicating no evidence for stronger Th1 responses. In contrast, slightly higher levels of IL-22 RNA were observed in FZ + LTA1 mice compared with FZ (P < 0.01 for day 6, Fig. 7G). IL-22 secretion by T-cells has previously been shown to be critical for epithelial repair during influenza infection33,34, but has not been explored as a mechanism in enhanced protection from enterotoxin based adjuvants. Thus, the protective effects of LTA1-adjuvanted flu vaccine are associated with CD4 T-cell activation and possibly IL-22 secretion.
Figure 4. LTA1 adjuvant enhances protection from H1N1 flu challenge after a single or prime/boost vaccination. (A) Schematic of mice prime vaccination and challenge: groups of C57Bl/6 mice (7–9 weeks of age) were left unvaccinated (unvacc.) or IN immunized with 3.6 μg HA-content FZ alone (FZ) or with 10 μg LTA1 (FZ + LTA1). After 14 days, mice were challenged with 2xLD50 H1N1. (B) Survival of H1N1 challenge and (C) weight change (as % from day of H1N1 challenge) in vaccinated young adult mice (n = 8). (D) Lung H1N1 viral RNA and (E) lung IL-6 RNA levels by qRT-PCR and quantified as fold change to unvaccinated/H1N1 infected mice with naïve mice added as an additional control were analyzed from day 6 post-H1N1 challenged mice (n = 3–4). (F) Correlation of lung RNA data from D&E with Spearman correlation coefficient (r) and P-value indicated. (G) Lung H1N1 viral RNA and (E) lung IL-6 RNA levels by qRT-PCR and quantified as fold change to unvaccinated/H1N1 infected mice were analyzed from day 3 or day 6 post-H1N1 challenged mice (n = 4) previously vaccinated prime/boost (day 0, 21) and challenged on day 35. (I) Correlation of lung RNA data from G&H with Spearman correlation coefficient (r) and P-value indicated. Data reported as mean ± SEM with significance indicated by log-rank (survival), t-test with Bonferroni-Dunn correction (weight), or by one-way ANOVA with Dunnett's post-test compared to FZ group (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ns = not significant).
In this study, we identified LTA1 as a safe, effective adjuvant for IN delivery with the potential to overcome past clinical safety issues observed with the LT-adjuvant flu vaccine. This is the first report of LTA1 enhancing vaccine protection against flu challenge or any infectious challenge. This clearly refutes the long-held belief that the A1 domain of LT is not stable enough to bind to or be taken up at mucosal surfaces and mediate immunologic stimulation. Additionally, this is the first study to demonstrate safety of an LT-based IN adjuvant using behavioral testing as evidence for lack of neurological toxicity in comparison with holotoxin. Lastly, we provide insight into the protective mechanisms of LTA1, identifying that B-cells are not required for adjuvanted vaccine protection against flu challenge but CD4 T-cells are highly activated. These results have direct implications for vaccine development and use of LTA1 as a novel IN adjuvant.

Figure 5. LTA1-mediated protection from H1N1 flu challenge is associated with humoral immunity post-challenge (serum IgM, IgG, and IgA antibodies, lung CD19 B-cells). Groups of C57Bl/6 mice (7–9 weeks of age, n = 4) were left unvaccinated (unvacc.) or IN immunized with 3.6 μg HA-content FZ alone (FZ) or with 10 μg LTA1 (FZ + LTA1) on day 0 (prime) or days 0 and 21 (prime/boost). All mice were challenged 14 days after the last vaccination with 2xLD50 H1N1. (A) Serum anti-FZ IgM, IgG, or IgA levels analyzed from day 3 or day 6 post-H1N1 challenged mice by ELISA (dotted line on IgM graphs at level of non-specific/background binding). (B) Total lung B-cells from day 3 or day 6 post-H1N1 challenged mice quantified by cytometric analysis of homogenized right lobe lung cells gated live-cell positive, dump channel (Gr1, CD11c) negative and CD19+. (C) Correlation of all post-challenge serum IgM, IgG, or IgA data to lung H1N1 viral RNA levels with Spearman correlation coefficient (r) and P-value indicated. Bars at mean ± SEM with significance by one-way ANOVA with Dunnett’s post-test compared to FZ group (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ns = not significant).
Figure 6. B-cells are not required for LTA1-mediated vaccine protection from H1N1 flu challenge. Groups (n = 6–7) of μMT mice or C57Bl/6 (WT) mice were left unvaccinated (unvaccin.) or IN immunized twice with 3.6 μg HA-content FZ alone (FZ) or with 10 μg LTA1 (FZ + LTA1) then challenged with 2xLD50 H1N1. (A) Survival of H1N1 challenge (left graph) and weight change (as % from day of H1N1 challenge, right graph) in FZ + LTA1 or unvaccin. μMT mice. (B) Lung H1N1 viral RNA analyzed from day 6 post-H1N1 challenged μMT and WT mice in indicated groups by qRT-PCR and quantified as fold change to WT: FZ group. (C) Representative dot plots of live-gated lung cells for dump channel (Gr1, CD11c) versus CD19 with B-cell gates from 6 days post-H1N1 challenge μMT and WT mice in indicated groups. (D) Compiled % lung B-cells from 6 days post-H1N1 challenge μMT and WT mice in indicated groups. (E) Compiled total lung B-cells (right lobe) from all cells collected 6 days post-H1N1 challenge from μMT and WT mice in indicated groups. (F) Serum anti-FZ IgM, IgG, and IgA ELISA raw data from day 6 post-H1N1 challenged μMT and WT mice in indicated groups (naïve = uninfected/unvaccinated mice). Data reported as mean ± SEM with significance indicated by log-rank (survival), t-test with Bonferroni-Dunn correction (weight), or by one-way ANOVA with Bonferroni's post-test for selected groups as shown (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
Figure 7. Activated CD4 T-cells are found in higher levels in LTA1 vaccinated animals post-H1N1 challenge. Groups (n = 6–7) of μMT mice or C57Bl/6 (WT) mice were left unvaccinated or IN immunized twice with FZ or FZ + LTA1, then all mice challenged with 2xLD50 H1N1. (A) Compiled % CD3 T-cells of live-gated lung cells (CD11c−, CD3+) 6 days post-H1N1 challenge from μMT and WT mice in indicated groups. (B) Compiled % NK cells of live-gated lung cells (NK1.1+, CD11c−, CD3−) 6 days post-H1N1 challenge from μMT and WT mice in indicated groups. (C) Compiled % CD4 (CD8−, NK1.1−), CD8 (CD8+, NK1.1), or NKT (CD8−, NK1.1+) cells of CD3 lung T-cells 6 days post-H1N1 challenge from μMT and WT mice in indicated groups. (D) Representative dot plots of CD4 vs CD69 markers expression on CD3 lung T-cells from indicated groups of WT mice 3 or 6 days post-H1N1 challenge. (E) Compiled % CD4+CD69+ of CD3 T-cells (CD8−, NK1.1−, CD3−) from indicated groups of WT mice 3 or 6 days post-H1N1 challenge. (F) Lung INFγ viral RNA levels analyzed from day 6 post-H1N1 challenged WT mice (n = 3–4) by qRT-PCR and quantified as fold change to unvaccinated/H1N1 infected mice. (G) Lung IL-22 viral RNA levels analyzed from day 6 post-H1N1 challenged WT mice (n = 3–4) by qRT-PCR and quantified as fold change to unvaccinated/H1N1 infected mice. Bars at mean ± SEM with significance by one-way ANOVA with Bonferroni’s post-test for selected groups as shown (A–C) or Dunnett’s post-test compared to FZ group (E-G, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ns = not significant).
Enterotoxin-based adjuvants are well known inducers of mucosal immunity, but their use in IN vaccination was hindered by increased risk of Bell's palsy (estimated at 13 cases per 10,000 vaccine recipients) compared with non-vaccinated individuals. One benefit of this past clinical observation is that other severe adverse events (e.g., local site reactogenicity, increased risk for cancer, birth defects, or pulmonary complications etc.) were never observed in pre-clinical and clinical studies. Thus, the specific safety risks that must be mitigated for a safe LT-based IN adjuvant are clearer than with an untried adjuvant. There is no pre-clinical model of Bell's palsy or other assessment of cranial nerve 1 reported with enterotoxin use. Therefore, we utilized the olfactory habituation-dishabituation test that assesses neurotoxicity through changes to cranial nerve 7 and olfactory system function (Fig. 1). While we previously speculated that removal of the B-subunit would limit neurological function (Fig. 1), this is the first demonstration of nontoxicity after nasal delivery of a LT-based adjuvant (at a 3–30x expected dose) using this methodology. Combined with our previous data demonstrating poor antigenic potential, this indicates LTA1 is an attractive option to overcome past clinical trial safety concerns. It is also worth mentioning, that LTA1 is also distinct from any other proposed IN enterotoxin adjuvant because it is based on LT protein and has no specific binding or cell-targeting component. For example, CTA1-DD has also been presented as an IN adjuvant but it is composed of a B-cell targeting synthetic component based on protein A and the A1 domain of CT (which is differs from LT by level of enzymatic activity and quality of immune responses). However, continued investigations with LTA1 both for neurological safety and in comparison with related adjuvants are warranted.

In our experiments, we utilized a flu vaccination model to determine the ability of LTA1 to improve vaccine efficacy. However, our results in this model are relevant since optimal protection against influenza has yet to be achieved. Seasonal and pandemic influenza (flu) are considered major public health threats despite annual vaccine campaigns. Addition of an adjuvant can overcome limited vaccine efficacy in high-risk populations (i.e., young, elderly) and also allow dose-sparing in case of vaccine shortages due to the 6–9 month production time for new vaccines. Lastly, while traditionally IN vaccines may not perform as well as injectables, they often are a popular needle-free option, as observed with FluMist® vaccination campaigns in US schools. Thus, an adjuvanted IN vaccine may improve vaccine efficacy particularly for high-risk groups and improve logistics of mass delivery during seasonal disease or pandemic outbreaks. In this study, we were able to show IN vaccination with an optimized dose of LTA1 admixed with an inactivated virus antigen improved survival, weight loss, and viremia from lethal H1N1 challenge. Therefore, LTA1, like its parent molecule LT, can boost immunity to flu antigens and has potential as a novel adjuvant for IN vaccine strategies.

We observed increases in humoral immunity in LTA1 adjuvanted vaccination that correlated with reduced lung viremia (Fig. 5). Despite this observation,µMT mice immunized twice with LTA1 + FZ were protected from severe weight loss and death from lethal H1N1 challenge and still exhibited reduced lung viremia (Fig. 6). Immunized mice did exhibit a slight decrease in weight post-challenge (5–10%) that differed from that observed in non-transgenic adult mice (seen in Supplementary Fig. 4). µMT mice have a disruption in the IgM heavy chain and therefore don’t develop mature B-cells and are estimated to have at least 50-fold more sensitivity to influenza infection. This indicates that classic B-cell functions, including antigen presentation and neutralizing antibodies are not required for LTA1 adjuvant effects, though B-cell responses may be necessary for maximal adjuvant-mediated protection. In both µMT and WT mice, we observed high levels of CD4 T-cells in the lungs during infection. This suggests that LTA1-mediated protective responses may be dependent upon CD4 T-cells or both B-cells and CD4 T-cells may play redundant roles in protection that should be explored in future studies.

In conclusion, these results support LTA1 as a unique mucosal adjuvant that has broad potential for flu and other vaccines. The impetus for this adjuvant development comes as successful control of infectious diseases through vaccination and other public health measures has reduced levels of circulating infections, thereby widening the gap between acceptable risks of side effects versus benefits from disease protection afforded by vaccination. This ever-evolving dialog alters how vaccines are formulated and scheduled, even precluding the use of older, effective live-attenuated vaccines or resulting in the phasing out of whole-killed vaccines due to reactogenicity and/or risk of disease, such as with pertussis and polio vaccines. However with altered vaccine formulations, tradeoffs in immunity are being created, including gaps in protection observed currently with both polio and pertussis vaccines that protect against clinical disease but not transmission. Adjuvants such as LTA1 that allow needle-free delivery and can promote mucosal immunity to subunit vaccination or inactivated vaccines (as reported here) can play the critical role of filling these key gaps in protection in the continuously changing landscape of vaccination and disease prevention policies.

Methods

Vaccines and adjuvant proteins. LTA1 and CT were produced from E. coli clones expressing recombinant proteins as previously described. Proteins were stored lyophilized and freshly resuspended prior to use (CT) or kept frozen at −20 °C until use (LTA1). The endotoxin content of all proteins was <1 EU/mg. The commercial trivalent flu vaccine: 2015–2016 Fluzone High-Dose® (FZ, Sanofi Pasteur, Swiftwater, PA) was purchased in 2015 from the Tulane University Hospital Pharmacy and contained 180μg/0.5 ml hemagglutinin (HA) from equal parts of A/California/07/2009 H1N1, A/Switzerland H3N2, and B/Phuket strains.

Mice. Seven-to-9-week old C57BL/6 female mice were purchased from The Jackson Laboratory (Bar Harbor, ME). For aged mice experiments, Balb/c mice were purchased at 6-to-8-weeks of age from NCI Charles River and aged in-house. Male and female µMT mice (strain B6.129S2-Lgdm1Cgn/J) were originally purchased from The Jackson Laboratory and bred in house for experiments. All mice were housed in sterile set-up with filter-top cages. Rodents were fed normal chow, with addition of weekly supplemental wet diet gel 76 A (ClearH2O, Portland, ME) for aged mice experiments. Mice were euthanized by CO2 inhalation and exsanguination (immunization studies).
or ketamine/xylazine overdose (flu and olfactory studies). All mouse experiments were approved by the Tulane University Institutional Animal Care and Use Committee and performed in accordance with relevant guidelines and regulations.

**Olfactory habituation-dishabituation test & nasal cavity histology.** Mice were individually housed and IN treated or left naive and tested by olfactory habituation-dishabituation 24h later as previously described\(^\text{23}\). Treatments included 30μg LTA1 (0.5 mg/ml) or 1–30μg CT (1 mg/ml). Trials were performed with 2cmx2cm filter paper freshly infused with 20μl mineral oil (Millipore Sigma), cheese trout bait (Berkeley, Columbia, SC, diluted 1:2 in ethanol), or shrimp oil (Atlas Mike’s, Fort Atkinson, WI) and by recording times investigating paper within ≤1 mm. After testing, select mice (n = 3/group) were euthanized using ketamine/xylazine and nasal cavities dissected according to established guidelines\(^\text{27}\) for formalin fixation, paraffin embedding, sectioning, H&E staining, and blindly analyzed by a pathologist using a score added for all three nasal sections per mouse (0 = normal, 1 = mild neutrophil inflammation and/or edematous changes, 2 = moderate degenerative or proliferative lesion, 3 = severe lesions with extensive damage to tissue architecture). Mast cells were analyzed using standard toluidine blue staining of paraffin embedded sections, counting total number purple cells per 100x microscopic field area added for two nasal sections (0 = <5 cells per area, 1 = 5–15/area, 2 = 15–25/area; 3 = 25–35/area; 4 = >35/area).

**Animal vaccination & H1N1 challenge.** Groups of mice (n = 4–8) were immunized with 3.6μg FZ (or 1.2μg of H1N1) containing 0–10μg LTA1 diluted in PBS (20–30μl total volume) IN by pipetting directly into nares of mice anesthetized with ketamine/xylazine or (aged mice only) inhaled isoflurane. Two weeks after the last immunization, mice were euthanized for sample collection or anesthetized again and challenged IN with mouse-adapted influenza A/California/07/2009 (H1N1) diluted in PBS (50μl total volume) at median lethal (1xLD50) or lethal (2xLD50) doses optimized for Balb/c or C57Bl/6 mouse strains. Mice were monitored for weight daily with loss of 30% initial body weight the endpoint for euthanasia. Some surviving mice were euthanized and perfused by cardiac puncture with saline, prior to inflation of lungs with 10% formalin for paraffin embedding, sectioning and H&E staining.

**Mouse sample collection & processing.** Serum was collected by cardiac puncture. BAL samples were collected by tracheal catherization and lavage with 1 ml PBS + protease inhibitor cocktail (Roche, Mannheim, Germany). Spleens were placed into C-tubes and homogenized via gentleMACS dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany). After filtration and red blood cell lysis (ACK lysis buffer, Millipore Sigma, St. Louis, MO), 1 x 10⁶ cells were plated in 200μl RPMI-10% FBS for antigen restimulation then supernatants harvested after 72 h culture for cytokine analyses.

**Antibody ELISAs & cytokine measurements.** Anti-FZ IgG1, IgG2a, and IgA antibody ELISAs were performed using CoStar 96-well flat bottom plates (Washington, DC) similar to as previously described\(^\text{13,24}\). Briefly, wells were coated with 1μg/ml FZ or recombinant standards (IgG1, IgG2a (Millipore Sigma) or IgA (Southern Biotech, Birmingham, AL)), incubated with sample dilutions, and detected with AKP-conjugated anti-mouse IgG1, IgG2a (BD Biosciences, Franklin Lakes, NJ) or HRP-conjugated anti-mouse IgA (Millipore Sigma). Results reported as ELISA units/ml (EU/ml) are averaged interpolated values around the standard curve midpoint. Cytokines were analyzed with thawed supernatants using Mouse CD8 T-cell Panel (Millipore Sigma) with a Luminex Bioplex 200 array reader (Bio-Rad, Hercules, CA).

**Lung RNA analyses.** Lungs were harvested at 3- or 6-days after infection. Left lung tissue from infected and control mice was minced and frozen at 10μl/mg in RTL buffer (Qiagen, Valencia CA). 20 mg lung tissue were homogenized with Lysing Matrix D-tubes using Fastprep24 using two 15 sec cycles and RNA extracted following Qiagen RNeasy Plus Mini Kit instructions. cDNA was generated using iScript reagents and protocol (Bio-Rad) and analyzed by real-time PCR using the Bio-Rad CFX connect detection system. H1N1 virus levels were quantified using influenza A primer and probe set obtained through BEI Resources, NIAID, NIH: Influenza Virus Real-Time RT-PCR Assay, NR-15592. Cytokines were quantified using PrimePCR™ Probe Assays for mouse Ifng, Il6, and Il22 (Bio-Rad). GAPDH was used as a housekeeping gene and quantified using Mm.PT.39a.1 qPCR assay. Statistical analysis was performed using GraphPad Prism v.7.0 or 8.0 (La Jolla, CA). Antibody and cytokine data were transformed for normalcy and homogeneity of variance prior to analysis (normal distribution using Shapiro-Wilk test). Statistics were performed using t-test using Bonferroni-Dunn correction.
or one- or two-way ANOVA with two-tailed Dunnett’s or Bonferroni post-tests for all compared to control or selected pairs respectively. Survival analyses were performed using log-rank test. Correlations were performed with Spearman’s rank-order correlation. Final figures were prepared using Adobe Illustrator software (San Jose, CA).

References

1. Vaccine preventable deaths and the Global Immunization Vision and Strategy, 2006–2015. MMWR Morb Mortal Wkly Rep 55, 511–513 (2006).
2. Warfel, J. M., Zimmerman, L. J. & Merkel, T. J. Accleral pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA 111, 787–792 (2014).
3. Warfel, J. M. & Edwards, K. M. Pertussis vaccines and the challenge of inducing durable immunity. Curr Opin Immunol 35, 48–54 (2015).
4. Wright, P. F. et al. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis 16, 1377–1384 (2016).
5. Herremans, T. M., Reimerink, J. H., Ruisman, A. M., Kimman, T. G. & Koopmans, M. P. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Infect Dis 162, 5011–5018 (1999).
6. McElhaney, J. E., Kuchel, G. A., Zhou, X., Swain, S. L. & Haynes, L. T Cell Immunity to Influenza in Older Adults: A Pathophysiologival Framework for Development of More Effective Vaccines. Front Immunol 7, 41 (2016).
7. Ruxin, J. et al. Emerging consensus in HIV/AIDS, malaria, tuberculosis, and access to essential medicines. Lancet 365, 618–621 (2005).
8. Ogura, P. L., Faden, H. & Welliver, R. C. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 14, 430–445 (2001).
9. Zaman, M., Chandru, S. & Toth, I. Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res 3, 100–109 (2013).
10. Sharma, S., Mukkarr, T. K., Benson, H. A. & Chen, Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci 98, 812–843 (2009).
11. Clements, J. D. & Norton, E. B. The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT: mSphere 3 (2018).
12. Clements, J. D., Hartzog, N. M. & Lyon, F. L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice unrelated to protein antigens. Vaccine 6, 269–277 (1988).
13. Norton, E. B., Lawson, L. B., Freytag, L. C. & Clements, J. D. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol 18, 546–551 (2011).
14. Mutich, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med 350, 896–903 (2004).
15. Lewis, D. J. et al. Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4, e6999 (2009).
16. Moss, J., Osborne, J. C. J., Fishman, P. H., Nakaya, S. & Robertson, D. C. Escherichia coli heat-labile enterotoxin. Ganglioside specificity and ADP-riboseyltransferase activity. J Biol Chem 256, 12861–12865 (1981).
17. Fahlen-Yrlid, L. et al. CD11c(high)dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization. J Immunol 183, 5032–5041 (2009).
18. Anosova, N. G. et al. Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer’s patches. Mucosal Immunol 1, 59–67 (2008).
19. Breton, C. F. et al. Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J Immunol 186, 5896–5906 (2011).
20. Leach, S., Clements, J. D., Kaim, J. & Lundgren, A. The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens. PLoS One 7, e51718 (2012).
21. Lauren, M., Holmgren, J., Lebens, M., Terrinoni, M. & Lundgren, A. Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signaling. Journal of Immunology 194, 3829–3839 (2015).
22. van Ginkel, F. W. et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun 73, 6892–6902 (2015).
23. Fukuyama, Y. et al. Nasal Administration of Cholera Toxin as a Mucosal Adjuvant Damages the Olfactory System in Mice. PLoS One 10, e0139368 (2015).
24. Norton, E. B., Lawson, L. B., Mahdi, Z., Freytag, L. C. & Clements, J. D. The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect Immun 80, 2426–2435 (2012).
25. Norton, E. B., Branco, L. M. & Clements, J. D. Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC). PLoS One 10, e0136302 (2015).
26. Zurbriggen, R., Metcalfe, I. C., Gluck, R., Viret, J. E. & Moser, C. Nonclinal safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert review of vaccines 2, 295–304 (2003).
27. Kettel, B. et al. Revised guides for organ sampling and trimming in rats and mice–Part 2. A joint publication of the RITA and NACAD groups. Exp Toxicol Pathol 55, 413–431 (2004).
28. Halsead, E. S. et al. GM-CSF overexpression after influenza a virus infection prevents mortality and moderates M1-like airway monocye/macrophage polarization. Respir Res 19, 3 (2018).
29. Dienz, O. et al. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol 5, 258–266 (2012).
30. McElhaney, J. E. et al. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 27, 2418–2423 (2009).
31. Graham, M. B. & Braciale, T. J. Resistance to and recovery from lethal influenza virus infection in B-lymphocyte-deficient mice. J Exp Med 186, 2063–2068 (1997).
32. Falsey, A. R., Treanor, J. J., Tornieporth, N., Capellan, J. & Gorse, G. J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 200, 172–180 (2009).
33. Pociask, D. A. et al. IL-22 is essential for lung epithelial repair following influenza infection. Am J Pathol 182, 1286–1296 (2013).
34. Dudakov, J. A., Hanash, A. M. & van den Brink, M. R. Interleukin-22: Immunobiology and pathology. Annu Rev Immunol 33, 747–785 (2015).
35. Bowman, C. C. & Clements, J. D. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids. Infect Immun 69, 1528–1535 (2001).
36. Ager, L., Lowenadler, B. & Lycke, N. A novel concept in mucosal adjuvanticity: the CTAl-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol Cell Biol 76, 280–287 (1998).
37. Cox, N. J., Trock, S. C. & Burke, S. A. Pandemic Preparedness and the Influenza Risk Assessment Tool (IRAT). *Current topics in microbiology and immunology* (2014).
38. Siver, H. G. The threat and prospects for control of an influenza pandemic. *Expert review of vaccines* 3, 35–42 (2004).
39. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza–United States, 1976–2007. *MMWR Morbidity and mortality weekly report* 59, 1057–1062 (2010).
40. Del Giudice, G. & Rappuoli, R. Inactivated and Adjuvanted Influenza Vaccines. *Current topics in microbiology and immunology* (2014).
41. Gill, M. A. & Schlaudecker, E. P. Perspectives from the Society for Pediatric Research: Decreased Effectiveness of the Live Attenuated Influenza Vaccine. *Pediatr Res* 83, 31–40 (2018).
42. Kitamura, D., Roes, J., Kuhn, R. & Rajewsky, K. A. B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. *Nature* 350, 423–426 (1991).
43. Norton, E. B., Clements, J. D., Voss, T. G. & Cardenas-Freytag, L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. *J Virol* 84, 2983–2995 (2010).

**Acknowledgements**
Research reported in this publication was supported by the NIAID/NIH under awards R01AI114697 and P20GM103629. The authors thank Clairissa Mulloy, Lauren Kodroff, Nini Zhou, Michelle Rojo, Leisheng Sun, Victoria Carle, as well as Joshua Currey, Diandra Ellis, Marcela Velasquez Lopez, and Addison Stone for their assistance in mouse studies and John Clements for helpful discussions. The following reagent was obtained through BEI Resources, NIAID, NIH: Influenza Virus Real-Time RT-PCR Assay, NR-15992.

**Author contributions**
E.B.N. planned the project, designed the experiments, and interpreted the data. E.V., A.J.H., M.K.N., L.B.L. and W.B.P. designed and performed the experiments. R.L.B. and Y.N. analyzed the data. E.B.N., E.V., R.L.B., M.K.N. wrote the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-51356-w.

Correspondence and requests for materials should be addressed to E.B.N.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019